Boston Scientific (BSX) Status Update summary

Market and Portfolio Growth

• Cardiology-served markets are valued at $40 billion in 2024, projected to grow at 8% CAGR through 2027, with U.S. and international growth rates at 27% and 18% year-to-date, respectively.

• Interventional Cardiology Therapies, Structural Heart Valves, and Coronary Therapies are key segments, each with high single-digit or double-digit growth rates.

• Drug-eluting therapies, including stents and balloons, are growing close to double digits globally, with DES now less than 5% of total sales, reflecting portfolio diversification.

• Complex PCI business, including Rotablator and Wolverine, is now larger than drug-eluting therapies, with U.S. growth in the mid-teens in Q3.

• Diversification into high-growth areas like mechanical circulatory support is part of the long-range plan.

Financial Performance and Sales Growth

• Cardiology achieved 23% global net sales growth year-to-date 2024, with 27% growth in the U.S. and 18% internationally.

• Electrophysiology saw 126% operational growth, Watchman 19%, and Interventional Cardiology Therapies 12% for the first nine months of 2024.

• All revenue growth rates are operational and exclude foreign currency impacts unless noted.

Product Launches and Clinical Advancements

• AGENT Drug-Coated Balloon received FDA approval and launched in the U.S.; expectations to double global business in 2025 over 2024.

• AVVIGO+ platform, featuring advanced AI capabilities, launched in 45+ countries, driving increased imaging usage and adoption, with IVUS used in 96% of AGENT cases.

• ACURATE Prime platform launched in Europe after CE Mark approval, offering enhanced clinical performance and expanded patient eligibility.

• FARAVIEW mapping software and FARAWAVE NAV catheter received PMA supplemental approval and went live in multiple accounts.

• WATCHMAN TruSteer and FARAPULSE Pulsed Field Ablation System received FDA approvals and launched in the U.S.